

Table. Reconciliation of results of current and prior meta-analyses.

	Current meta-analysis	Huang 2019 PMID 31296196	Rota 2019 PMID: 31046087	Wang 2018 PMID 2997938	Snowsill (NHS)*, 2018 PMID 26013989	Coureau 2016 PMID: 27211572	Usman Ali 2016 PMID: 2713053	Fu 2014 PMID 25307063	Manser (Cochrane), 2013 PMID 23794187	Humphrey (USPSTF) 2013 PMID: 23897166
Number of studies	9	9	7	4	4	5	4	4	1	4
Efficacy for lung cancer mortality reduction	0.84 (0.75, 0.93)	0.83 (0.76, 0.90)	0.80 (0.71, 0.90)	1.13 (0.78, 1.64) Exclude MILD 1.02 (0.66, 1.58)	0.94 (0.74, 1.19) Exclude MILD 0.85 (0.74, 0.98)	Meta-analysis not performed due to lack of power, methodologic heterogeneity	Annual vs. usual 1.30 (0.81, 2.11) CXR Biennial vs. usual 1.45 (0.79, 2.69) LDCT vs. CXR (n = 1) 0.80 (0.70, 0.92)	0.84 (0.74, 0.96) Studies mislabeled	0.80 (0.70, 0.92)	Meta-analysis not performed due to heterogeneity
Heterogeneity	0%	1%	19%	87% Excluding MILD 85%	43% 6.9%	Not estimated	40% NA NA	48%	Not applicable (1 study)	High
Efficacy for overall mortality reduction	0.96 (0.91, 1.01)	0.95 (0.90, 1.00)	Not reported	Not reported	1.00 (0.87, 1.16)	Meta-analysis not performed due to lack of	Annual LDCT vs. usual	1.04 (0.72, 1.51) Studies mislabeled	0.94 (0.88, 1.00)	Meta-analysis not performed

					Exclude MILD 0.95 (0.89, 1.00)	power, methodologic heterogeneity	1.38 (0.86, 2.22) Biennial vs. usual 1.45 (0.79, 2.69) LDCT vs. CXR 0.94 (0.88, 0.998)			due to heterogeneity
Heterogeneity	0%	0%	Not reported	Not reported	57% 0%	Not estimated	80% NA NA	48%	Not applicable (1 study)	High